Hansoh Pharmaceutical Group (SEHK:3692) Net Margin Strength Backs Bullish Narratives

Simply Wall St.03-30

Hansoh Pharmaceutical Group (SEHK:3692) just posted its FY 2025 first half results with revenue of C¥7.4b and basic EPS of C¥0.53, against a trailing twelve month backdrop of C¥15.0b in revenue and C¥...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2623340500?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-03-30 21:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2623340500","market":"hk","top_or_hot":-1,"title":"Hansoh Pharmaceutical Group (SEHK:3692) Net Margin Strength Backs Bullish Narratives","media":"Simply Wall St.","content":"<div>\n<p>Hansoh Pharmaceutical Group (SEHK:3692) just posted its FY 2025 first half results with revenue of C¥7.4b and basic EPS of C¥0.53, against a trailing twelve month backdrop of C¥15.0b in revenue and C¥...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-net-margin-strength-bac\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharmaceutical Group (SEHK:3692) Net Margin Strength Backs Bullish Narratives</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharmaceutical Group (SEHK:3692) Net Margin Strength Backs Bullish Narratives\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-30 21:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-net-margin-strength-bac><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Hansoh Pharmaceutical Group (SEHK:3692) just posted its FY 2025 first half results with revenue of C¥7.4b and basic EPS of C¥0.53, against a trailing twelve month backdrop of C¥15.0b in revenue and C¥...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-net-margin-strength-bac\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BLSX","symbol_name":"Tradr 2X Long BLSH Daily ETF","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-net-margin-strength-bac","article_id":"2623340500","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-3692/hansoh-pharmaceutical-group-shares/news/hansoh-pharmaceutical-group-sehk3692-net-margin-strength-bac","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2623340500","pubTimestamp":1774876230,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Hansoh Pharmaceutical Group (SEHK:3692) just posted its FY 2025 first half results with revenue of C¥7.4b and basic EPS of C¥0.53, against a trailing twelve month backdrop of C¥15.0b in revenue and C¥0.93 in EPS off C¥5.6b in net income, as well as earnings growth of 27.1% over the past year. The company has seen revenue move from C¥6.5b and EPS of C¥0.46 in 1H FY 2024 to C¥5.8b and EPS of C¥0.28 in 2H FY 2024, and now to C¥7.4b and EPS of C¥0.53 in 1H FY 2025. This sets up a story where rich...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BLSX":"Tradr 2X Long BLSH Daily ETF","BLSG":"2倍做多BLSH ETF-Leverage Shares","BK1583":"高瓴概念","BK1589":"北水核心资产","BK1191":"制药","BK4112":"金融交易所和数据","03692":"翰森制药"},"translate_title":"豪森药业集团（SEHK：3692）净利润强劲支持看涨叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLSX":0.6,"BLSG":0.6,"03692":1.96},"content_text":"Hansoh Pharmaceutical Group (SEHK:3692) just posted its FY 2025 first half results with revenue of C¥7.4b and basic EPS of C¥0.53, against a trailing twelve month backdrop of C¥15.0b in revenue and C¥0.93 in EPS off C¥5.6b in net income, as well as earnings growth of 27.1% over the past year. The company has seen revenue move from C¥6.5b and EPS of C¥0.46 in 1H FY 2024 to C¥5.8b and EPS of C¥0.28 in 2H FY 2024, and now to C¥7.4b and EPS of C¥0.53 in 1H FY 2025. This sets up a story where rich margins and solid profit conversion are central to how this set of results lands with investors. See our full analysis for Hansoh Pharmaceutical Group. With the numbers on the table, the next step is to test them against the main stories investors follow around Hansoh, highlighting where the fresh results support those narratives and where they start to push back. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:3692 Earnings & Revenue History as at Mar 2026 AdvertisementNet Margin At 37% Supports High Profit Conversion  Over the last 12 months, Hansoh converted C¥15.0b of revenue into C¥5.6b of net income, giving a 37.0% net profit margin compared with 35.7% a year earlier. Supporters of the bullish view point to this margin profile as a key strength, and the numbers give them solid backing:\n     Earnings grew 27.1% over the past year, while compounding at 17.4% per year over five years. This lines up with the idea of a business that has turned high profitability into consistent growth. The move from 35.7% to 37.0% margin suggests recent growth has not relied only on higher revenue but also on keeping a large share of each C¥1 in sales as profit.    Premium 31.8x P/E Versus Peers  The stock trades on a trailing P/E of 31.8x, compared with a Hong Kong pharma industry average of 14.8x and a peer average of 23.1x, so the multiple is clearly higher than both reference points. Skeptics focus on this premium and the figures help explain why they are cautious:\n     Forecast earnings growth of about 11.9% per year sits slightly below the 12.4% figure cited for the Hong Kong market, so the current P/E premium is not matched by a higher earnings growth rate in the data provided. With the share price at HK$33.08 and the analyst target at HK$46.22, the implied upside is around 40%, yet the premium P/E means any disappointment versus those growth expectations could have a larger impact on valuation than for cheaper peers.    On top of these mixed valuation signals, many investors like to balance the earnings story with a broader set of viewpoints on the company through recent community discussion, especially when the current multiple and growth profile pull in different directions. 📊 Read the what the Community is saying about Hansoh Pharmaceutical Group. Half-Year Swings Inside A 27.1% Earnings Growth Story  Across the last three half years, revenue moved from C¥6.5b in 1H FY 2024 to C¥5.8b in 2H FY 2024 and then to C¥7.4b in 1H FY 2025, while net income (excluding extra items) tracked at C¥2.7b, C¥1.6b and C¥3.1b respectively, contributing to 27.1% earnings growth over the most recent year. What stands out for bullish investors is how this pattern still fits a growth story, though the data also keeps expectations in check:\n     The trailing 12 month revenue of C¥15.0b and net income of C¥5.6b show that, even with swings between halves, the company has delivered a high earnings base that matches the multi year growth rates cited. At the same time, forecasts of roughly 11.5% annual revenue growth and 11.9% annual earnings growth point to a steadier, mid range pace ahead rather than a sharp acceleration. This can help set more balanced expectations for how these half year moves fit into the longer run.    Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Hansoh Pharmaceutical Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. Given all these moving parts, how do you feel about the balance of optimism and risk around Hansoh today? Take a moment to check the figures that matter most to you, then see what sits behind the rewards investors are already watching with the 4 key rewards See What Else Is Out There Hansoh pairs rich margins with a premium 31.8x P/E, so the valuation looks demanding compared with peers and not clearly backed by higher forecast growth. If that premium makes you cautious, it is worth checking companies that combine stronger value signals with quality fundamentals using the 240 high quality undervalued stocks.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Hansoh Pharmaceutical Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2623340500","isCrawlerRequest":true}